Clinically non-functioning pituitary adenomas: Pathogenic, diagnostic and therapeutic aspects

Ostrom, 2013, CBTRUS Statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010, Neurol Oncol, 15, 1 Ezzat, 2004, The prevalence of pituitary adenomas: a systematic review, Cancer, 101, 613, 10.1002/cncr.20412 Molitch, 2009, Pituitary tumours: pituitary incidentalomas, Best Pract Res Clin Endocrinol Metab, 23, 667, 10.1016/j.beem.2009.05.001 Molitch, 2017, Diagnosis and treatment of pituitary adenomas, a review, JAMA, 317, 516, 10.1001/jama.2016.19699 Orija, 2012, Pituitary incidentaloma, Best Pract Res Clin Endocrinol Metab, 26, 47, 10.1016/j.beem.2011.07.003 Fontana, 2009, Epidemiology of pituitary adenoma: results of the first Swiss study, Rev Med Suisse, 5, 2172 Fernandez, 2010, Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK), Clin Endocrinol, 72, 377, 10.1111/j.1365-2265.2009.03667.x Raappana, 2010, Incidence of pituitary adenomas in Northern Finland in 1992–2007, J Clin Endocrinol Metab, 95, 4268, 10.1210/jc.2010-0537 Tjörnstrand, 2014, The incidence rate of pituitary adenomas in western Sweden for the period 2001–2011, Eur J Endocrinol, 171, 519, 10.1530/EJE-14-0144 Agustsson, 2015, The epidemiology of pituitary adenomas in Iceland, 1955–2012: a nationwide population-based study, Eur J Endocrinol, 173, 655, 10.1530/EJE-15-0189 Fainstein Day, 2016, Incidence and prevalence of clinically-relevant pituitary adenomas: retrospective cohort study in a Health Management Organization in Buenos Aires, Argentina, Arch Endocrinol Metab, 60, 554, 10.1590/2359-3997000000195 Jaffe, 2006, Clinically non-functioning pituitary adenoma, Pituitary, 9, 317, 10.1007/s11102-006-0412-9 Molitch, 2008, Nonfunctioning pituitary tumors and pituitary incidentalomas, Endocrinol Metab Clin North Am, 37, 151, 10.1016/j.ecl.2007.10.011 Monson, 2000, The epidemiology of endocrine tumours, Endocr Relat Cancer, 7, 29, 10.1677/erc.0.0070029 Grossman, 2009, The molecular biology of pituitary tumors: a personal perspective, Pituitary, 12, 265, 10.1007/s11102-008-0158-7 Melmed, 2011, Pathogenesis of pituitary tumors, Nat Rev Endocrinol, 7, 257, 10.1038/nrendo.2011.40 Afflorei, 2014, Epidemiology and etiopathogenesis of pituitary adenomas, J Neurooncol, 117, 379, 10.1007/s11060-013-1354-5 Thakker, 2014, Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4), Mol Cell Endocrinol, 386, 2, 10.1016/j.mce.2013.08.002 Rothenbuhler, 2010, Clinical and molecular genetics of Carney complex, Best Pract Res Cli Endocrinol Metab, 24, 389, 10.1016/j.beem.2010.03.003 Hernández-Ramírez, 2015, Landscape of familial isolated and young-onset pituitary adenomas: prospective diagnosis in AIP mutation carriers, Clin Endocrinol Metab, 100, 1242, 10.1210/jc.2015-1869 Caimari, 2016, Novel genetic causes of pituitary adenomas, Clin Cancer Res, 22, 5030, 10.1158/1078-0432.CCR-16-0452 Vergès, 2002, Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study, J Clin Endocrinol Metab, 87, 457, 10.1210/jcem.87.2.8145 Stergiopolus, 2003, Human tumors associated with Carney complex and germline PRKAR1A mutations: a protein kinase A disease!, FEBS Lett, 546, 59, 10.1016/S0014-5793(03)00452-6 Beckers, 2013, Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene, Endocr Rev, 34, 239, 10.1210/er.2012-1013 Simpson, 2004, Molecular pathology shows p16 methylation in nonadenomatous pituitaries from patients with Cushing's disease, Clin Cancer Res, 10, 1780, 10.1158/1078-0432.CCR-1127-3 Vlotides, 2007, Pituitary tumor-transforming gene: physiology and implications for tumorigenesis, Endocr Rev, 28, 165, 10.1210/er.2006-0042 McCabe, 2003, Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour, Clin Endocrinol, 58, 141, 10.1046/j.1365-2265.2003.01598.x Filippella, 2006, Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study, Clin Endocrinol, 65, 536, 10.1111/j.1365-2265.2006.02630.x Newey, 2013, Whole-exome sequencing studies of nonfunctioning pituitary adenomas, J Clin Endocrinol Metab, 98, E796, 10.1210/jc.2012-4028 Pernicone, 1997, Pituitary carcinoma: a clinicopathologic study of 15 cases, Cancer, 79, 804, 10.1002/(SICI)1097-0142(19970215)79:4<804::AID-CNCR18>3.0.CO;2-3 Ragel, 2004, Pituitary carcinoma: a review of the literature, Neurosurg Focus, 16, E7, 10.3171/foc.2004.16.4.8 Colao, 2010, Pituitary carcinomas, Front Horm Res, 38, 94, 10.1159/000318499 Heaney, 2011, Clinical review: pituitary carcinoma: difficult diagnosis and treatment, J Clin Endocrinol Metab, 96, 3649, 10.1210/jc.2011-2031 Bartkova, 2006, Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints, Nature, 444, 633, 10.1038/nature05268 Chesnokova, 2007, Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth, Cancer Res, 67, 10564, 10.1158/0008-5472.CAN-07-0974 Chesnokova, 2008, p21(Cip1) restrains pituitary tumor growth, Proc Natl Acad Sci U S A, 105, 17498, 10.1073/pnas.0804810105 Uccella, 2005, Aneuploidy, centrosome alteration and securin overexpression as features of pituitary somatotroph and lactotroph adenomas, Anal Quant Cytol Histol, 27, 241 Yang, 2016, Genetic aspects of pituitary carcinoma: a systematic review, Medicine (Baltimore), 95, e5268, 10.1097/MD.0000000000005268 Øystese, 2016, Non-functioning pituitary adenomas: growth and aggressiveness, Endocrine, 53, 28, 10.1007/s12020-016-0940-7 Dekkers, 2008, Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas, J Clin Endocrinol Metab, 93, 3717, 10.1210/jc.2008-0643 Grochowicki, 1991, Pituitary adenomas: automatic static perimetry and Goldmann perimetry. A comparative study of 345 visual field charts, Br J Ophthalmol, 75, 219, 10.1136/bjo.75.4.219 Fujimoto, 2002, Criteria for early detection of temporal hemianopia in asymptomatic pituitary tumor, Eye, 16, 731, 10.1038/sj.eye.6700165 Heuser, 2004, Neuro-ophthalmic findings in sarcoidosis, Acta Ophthalmol Scand, 82, 723, 10.1111/j.1600-0420.2004.00348.x Bansal, 2014, Isolated pupil-involving third nerve palsy as the first presentation of sarcoidosis, Neuroophthalmol, 38, 278, 10.3109/01658107.2014.928826 Jovanovic, 2014, Central nervous system involvement in hemophagocytic lymphohistiocytosis: a single-center experience, Pediatr Neurol, 50, 233, 10.1016/j.pediatrneurol.2013.10.014 Habu, 2015, Pituitary metastasis: current practice in Japan, J Neurosurg, 123, 998, 10.3171/2014.12.JNS14870 Ravnik, 2016, Hypophyseal metastatsis: a report of three cases and literature review, Neurol Neurochir Pol, 50, 511, 10.1016/j.pjnns.2016.08.007 Vargas, 2015, Clinical characteristics and treatment outcome of 485 patients with nonfunctioning pituitary macroadenomas, Int J Endocrinol, 2015, 756069, 10.1155/2015/756069 Möller-Goede, 2011, Pituitary apoplexy: re-evaluation of risk factors for bleeding into pituitary adenomas and impact on out-come, Eur J Endocrinol, 164, 39, 10.1530/EJE-10-0651 Vargas, 2014, Pituitary apoplexy in nonfunctioning pituitary macroadenomas: a case–control study, Endocr Pract, 20, 1274, 10.4158/EP14120.OR Briet, 2015, Pituitary apoplexy, Endocrinol Metab Clin North Am, 44, 199, 10.1016/j.ecl.2014.10.016 Capatina, 2015, Pituitary tumor apoplexy, Eur J Endocrinol, 172, R179, 10.1530/EJE-14-0794 Semple, 2007, Clinical relevance of precipitating factors in pituitary apoplexy, Neurosurgery, 61, 956, 10.1227/01.neu.0000303191.57178.2a Treip, 1961, Pathology of human and experimental pituitary tumors, Proc R Soc Med, 54, 623 Osamura, 2008, Pathology of the human pituitary adenomas, Histochem Cell Biol, 130, 495, 10.1007/s00418-008-0472-1 Tortosa, 2017, Novel aspects in histopathology of the pituitary gland, Endocrinol Diab Nutr, 64, 152 Asa, 2008, Practical pituitary pathology: what does the pathologist need to know, Arch Pathol Lab Med, 132, 1231, 10.5858/2008-132-1231-PPPWDT McDonald, 2017, A rational starting place for the immunohistochemical characterization of pituitary adenomas, Arch Pathol Lab Med, 141, 104, 10.5858/arpa.2016-0082-OA Balogun, 2015, Null cell adenomas of the pituitary gland: an institutional review of their clinical imaging and behavioral characteristics, Endocr Pathol, 26, 63, 10.1007/s12022-014-9347-2 Cooper, 2010, Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes, Horm Cancer, 1, 80, 10.1007/s12672-010-0014-x Wang, 2009, Clinicopathological characterization of TSH-producing adenomas: special reference to TSH-immunoreactive but clinically non-functioning adenomas, Endocr Pathol, 4, 209, 10.1007/s12022-009-9094-y Mayson, 2015, Silent pituitary adenomas, Endocrinol Metab Clin North Am, 44, 79, 10.1016/j.ecl.2014.11.001 Chinezu, 2017, Silent somatotroph tumor revisited from a study of 80 patients with and without acromegaly and review of the literature, Eur J Endocrinol, 176, 195, 10.1530/EJE-16-0738 Budan, 2016, Multiple pituitary adenomas: a systematic review, Front Endocrinol, 7, 1, 10.3389/fendo.2016.00001 Ramírez, 2012, Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study, J Clin Endocrinol Metab, 97, 1745, 10.1210/jc.2011-3163 Pivonello, 2004, Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment, J Clin Endocrinol Metab, 89, 1674, 10.1210/jc.2003-030859 Taboada, 2007, Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas, Eur J Endocrinol, 156, 65, 10.1530/eje.1.02313 Burger, 1986, The use of the monoclonal antigen Ki-67 in the identification of proliferating cells: application to surgical neuropathology, Am J Surg Pathol, 10, 611, 10.1097/00000478-198609000-00003 Chacko, 2010, The clinical significance of MiB-1 labeling index in pituitary adenomas, Pituitary, 13, 244, 10.1007/s11102-010-0242-7 Chanson, 2015, Management of clinically non-functioning pituitary adenoma, Ann Endocrinol (Paris), 76, 239, 10.1016/j.ando.2015.04.002 DeLellis, 2004 Figarella-Bronger, 2006, The WHO classification of human pituitary tumors: comments, Acta Neuropathol, 111, 71, 10.1007/s00401-005-1099-0 Zada, 2011, Atypical pituitary adenomas: incidence, clinical characteristics and implications, J Neurosurg, 114, 336, 10.3171/2010.8.JNS10290 Nomikos, 2004, Impact of primary surgery on pituitary function in patients with non-functioning pituitary adenomas – a study on 721 patients, Acta Neurochirug, 146, 27, 10.1007/s00701-003-0174-3 Wichers-Rother, 2004, Non-functioning pituitary adenomas: endocrinological and clinical outcome after transsphenoidal and transcranial surgery, Exp Clin Endocrinol Diab, 112, 323, 10.1055/s-2004-820914 Dekkers, 2006, Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma, J Clin Endocrinol Metab, 91, 1796, 10.1210/jc.2005-2552 Greenman, 2003, Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth, Clin Endocrinol, 58, 763, 10.1046/j.1365-2265.2003.01784.x Arafah, 1995, Dynamics of prolactin secretion in patients with hypopituitarism and pituitary macroadenomas, J Clin Endocrinol Metab, 80, 3507 Karavitaki, 2006, Do the limits of serum prolactin in disconnection hyperprolactinemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma, Clin Endocrinol, 65, 525, 10.1111/j.1365-2265.2006.02627.x Melgar, 2016, Current diagnosis and treatment of hyperprolactinemia, Rev Med IMSS, 54, 111 Saeger, 2007, Pathophysiological classification of pituitary tumors: 10 years experience with the German Pituitary Tumor Registry, Eur J Endocrinol, 156, 203, 10.1530/eje.1.02326 Snyder, 1985, Gonadotroph cell adenomas of the pituitary, Endocr Rev, 6, 552, 10.1210/edrv-6-4-552 Ho, 1997, The clinicopathological characteristics of gonadotroph cell adenoma: a study of 118 cases, Hum Pathol, 2, 905, 10.1016/S0046-8177(97)90005-8 Daneshdoost, 1993, Identification of gonadotroph adenomas in men with clinically nonfunctioning adenomas by the luteinizing hormone beta subunit response to thyrotropin-releasing hormone, J Clin Endocrinol Metab, 77, 1255 Daneshdoost, 1991, Recognition of gonadotroph adenomas in women, N Engl J Med, 324, 589, 10.1056/NEJM199102283240904 Djerassi, 1995, Gonadotroph adenoma in a premenopausal woman secreting follicle-stimulating hormone and causing ovarian hyperstimulation, J Clin Endocrinol Metab, 80, 591 Higham, 2016, Hypopituitarism, Lancet, 388, 2403, 10.1016/S0140-6736(16)30053-8 Hartman, 2002, Which patients do not require a GH stimulation test for the diagnosis of GH deficiency, J Clin Endocrinol Metab, 87, 477, 10.1210/jcem.87.2.8216 Rennert, 2007, Imaging of sellar and parasellar lesions, Clin Neurol Neurosurg, 109, 111, 10.1016/j.clineuro.2006.11.001 Bonneville, 2016, Magnetic resonance imaging of pituitary tumors, Front Horm Res, 45, 97, 10.1159/000442327 Nishioka, 2012, Correlation between histological subtypes and MRI findings in clinically nonfunctioning pituitary adenomas, Endocr Pathol, 23, 151, 10.1007/s12022-012-9208-9 Donovan, 1995, The natural history of the pituitary inicidentaloma, Arch Intern Med, 155, 181, 10.1001/archinte.1995.00430020067008 Sano, 2003, A survey of pituitary incidentaloma in Japan, Eur J Endocrinol, 149, 123, 10.1530/eje.0.1490123 Fainstein Day, 2004, Retrospective multicentric study of pituitary incidentalomas, Pituitary, 7, 145, 10.1007/s11102-005-1757-1 Arita, 2006, Natural course of incidentally found nonfunctioning pituitary adenoma, with special reference to pituitary apoplexy during follow up examination, J Neurosurg, 104, 884, 10.3171/jns.2006.104.6.884 Dekkers, 2007, The natural course of non-functioning pituitary macroadenomas, Eur J Endocrinol, 156, 217, 10.1530/eje.1.02334 Karavitaki, 2007, What is the natural history of nonoperated nonfunctioning pituitary adenomas? Clin Endocrinol, J Clin Endocrinol Metab, 67, 938 Imran, 2016, Analysis and natural history of pituitary incidentalomas, Eur J Endocrinol, 175, 1, 10.1530/EJE-16-0041 Fernández-Balsells, 2011, Natural history of nonfunctioning pituitary adenomas and incidentalomas: a systematic review and metaanalysis, J Clin Endocrinol Metab, 96, 905, 10.1210/jc.2010-1054 Guinto, 2003, Hypophyseal macroadenomas. A neurosurgical challenge, Cir Cir, 71, 350 Castinetti, 2015, Non-functioning pituitary adenoma: when and how to operate? What pathologic criteria for typing, Ann Endocrinol, 76, 220, 10.1016/j.ando.2015.04.007 Dallapiazza, 2015, Outcomes of endoscopic transsphenoidal surgery, Endocrinol Metab Clin North Am, 44, 105, 10.1016/j.ecl.2014.10.010 Reddy, 2001, Can we stop imaging in surgically treated and radiotherapy naïve patients with non-functioning pituitary adenomas, Eur J Endocrinol, 165, 739, 10.1530/EJE-11-0566 Marazuela, 1994, Recovery of visual and endocrine function following transsphenoidal surgery of large nonfunctioning pituitary adenomas, J Endocrinol Invest, 17, 703, 10.1007/BF03347763 Vargas, 2014, Efficacy and safety of external beam radiation therapy in non-functioning pituitary adenomas: a case–control, nested in a cohort study, J Radiotherapy Pract, 13, 87, 10.1017/S1460396913000071 Ntali, 2015, Efficacy and complications of pituitary irradiation, Endocrinol Metab Clin North Am, 44, 117, 10.1016/j.ecl.2014.10.009 Minniti, 2005, Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years, J Clin Endocrinol Metab, 90, 800, 10.1210/jc.2004-1152 Erfurth, 2004, Doubled mortality rate in irradiated patients reoperated for regrowth of a macroadenoma of the pituitary gland, Eur J Endocrinol, 150, 497, 10.1530/eje.0.1500497 González, 2016, Health-related quality of life in patients with nonfunctioning pituitary adenomas undergoing postoperative radiation therapy: a case–control study, Endocr Pract, 22, 540, 10.4158/EP151100.OR Nielsen, 2007, Nonfunctioning pituitary adenoma: incidence, causes of death and quality of life in relation to pituitary function, Pituitary, 10, 67, 10.1007/s11102-007-0018-x Karppinen, 2016, Health-related quality of life in patients treated for nonfunctioning pituitary adenomas during the years 2000–2010, Clin Endocrinol, 84, 532, 10.1111/cen.12967 Florio, 2008, Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study, Endocr-Rel Cancer, 15, 583, 10.1677/ERC-07-0271 Colao, 2003, Somatostatin analogs in the treatment of non-GH secreting pituitary adenomas, Endocrine, 20, 279, 10.1385/ENDO:20:3:279 Colao, 2008, Medical therapy for nonfunctioning pituitary adenomas, Endocr-Rel Cancer, 15, 905, 10.1677/ERC-08-0181 Greenman, 2016, Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists, Eur J Endocrinol, 175, 63, 10.1530/EJE-16-0206 Melmed, 2016, Pituitary medicine from discovery to patient-focused outcomes, J Clin Endocrinol Metab, 101, 769, 10.1210/jc.2015-3653